Show Stocks and Investing Publications • Thu, May 5, 2022
Gena Wang Maintained (VRTX) at Buy and Held Target at $291 on, May 5th, 2022
gena-wang-maintained-vrtx-at-buy-and-held-target-at-291-on-may-5th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $291 on, May 5th, 2022.
Gena has made no other calls on VRTX in the last 4 months.
There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 3 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022
- Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $249 on, Friday, April 22nd, 2022
- Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $274 on, Wednesday, April 6th, 2022
These are the ratings of the 7 analyists that currently disagree with Gena
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 3rd, 2022
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $300 on, Tuesday, April 5th, 2022
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
- Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
- Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022